Skip to main content

XyloCor Therapeutics

October 18, 2023
Franciscan B
Gene/Cell Therapy
Company Description: XyloCor Therapeutics, Inc. is a private, clinical stage biopharmaceutical company developing potential best in class gene therapies to transform outcomes for patients with cardiovascular disease. There are 10.8 million patients in the United States with chronic stable angina, of which 1.4 million are refractory angina patients with no remaining treatment options. The Company's lead gene therapy candidate is XC001, which is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow. By restoring blood flow, chest pain associated with refractory angina should decrease, potentially improving patients' quality of life by enabling them to engage in daily physical activities that would otherwise cause pain.
Albert Gianchetti, Chief Executive Officer - XyloCor Therapeutics